In the patients enrolled in the cross-over study RBP4 circulating levels were significantly reduced by HDF treatment compared to BD (99.2 ± 48.9 versus 140.1 ± 54.1 mg/L, P < 0.05; Figure 5(a)). This evidence concerns the gene RBP4 and Behcet disease.